Display options
Cite
Nocera NF, Lee MC, De La Cruz LM, et al. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol. 2016;7:356doi: 10.3389/fphar.2016.00356.
Nocera, N. F., Lee, M. C., De La Cruz, L. M., Rosemblit, C., & Czerniecki, B. J. (2016). Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Frontiers in pharmacology, 7356. https://doi.org/10.3389/fphar.2016.00356
Nocera, Nadia F, et al. "Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention." Frontiers in pharmacology vol. 7 (2016): 356. doi: https://doi.org/10.3389/fphar.2016.00356
Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol. 2016 Oct 06;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016. PMID: 27766079; PMCID: PMC5052279.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2016 Oct 06;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016.

Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Frontiers in pharmacology

Nadia F Nocera, M Catherine Lee, Lucy M De La Cruz, Cinthia Rosemblit, Brian J Czerniecki

Affiliations

  1. Department of Surgery, University of Pennsylvania Perelman School of Medicine Philadelphia, PA, USA.
  2. Comprehensive Breast Program, H. Lee Moffitt Cancer Center Tampa, FL, USA.

PMID: 27766079 PMCID: PMC5052279 DOI: 10.3389/fphar.2016.00356

Abstract

The ErbB/B2 (HER-2/neu) oncogene family plays a critical role in the development and metastatic spread of several tumor types including breast, ovarian and gastric cancer. In breast cancer, HER-2/neu is expressed in early disease development in a large percentage of DCIS lesions and its expression is associated with an increased risk of invasion and recurrence. Targeting HER-2 with antibodies such as trastuzumab or pertuzumab has improved survival, but patients with more extensive disease may develop resistance to therapy. Interestingly, response to HER-2 targeted therapies correlates with presence of immune response genes in the breast. Th1 cell production of the cytokines interferon gamma (IFNγ) and TNFα can enhance MHC class I expression, PD-L1 expression, augment apoptosis and tumor senescence, and enhances growth inhibition of many anti-breast cancer agents, including anti-estrogens and HER-2 targeted therapies. Recently, we have identified that a loss of anti-HER-2 CD4 Th1 in peripheral blood occurs during breast tumorigenesis and is dramatically diminished, even in Stage I breast cancers. The loss of anti-HER-2 Th1 response is specific and not readily reversed by standard therapies. In fact, this loss of anti-HER-2 Th1 response in peripheral blood correlates with lack of complete response to neoadjuvant therapy and diminished disease-free survival. This defect can be restored with HER-2 vaccinations in both DCIS and IBC. Correcting the anti-HER-2 Th1 response may have significant impact in improving response to HER-2 targeted therapies. Development of immune monitoring systems for anti-HER-2 Th1 to identify patients at risk for recurrence could be critical to improving outcomes, since the anti-HER-2 Th1 response can be restored by vaccination. Correction of the cellular immune response against HER-2 may prevent recurrence in high-risk patients with DCIS and IBC at risk of developing new or recurrent breast cancer.

Keywords: HER2; Th1 immunity; breast cancer; cancer vaccines; immunotherapy

References

  1. Cancer Immunol Res. 2015 Jan;3(1):37-47 - PubMed
  2. Rambam Maimonides Med J. 2014 Oct 29;5(4):e0024 - PubMed
  3. Int J Cancer. 2011 Jan 15;128(2):390-401 - PubMed
  4. Melanoma Res. 2012 Jun;22(3):236-43 - PubMed
  5. J Transl Med. 2013 Jan 15;11:16 - PubMed
  6. Nature. 2013 Feb 21;494(7437):361-5 - PubMed
  7. Ann Oncol. 2015 Feb;26(2):259-71 - PubMed
  8. Int J Dev Biol. 2011;55(7-9):685-96 - PubMed
  9. Cancer Res. 2010 Nov 1;70(21):8368-77 - PubMed
  10. Eur J Immunol. 2013 Oct;43(10):2554-65 - PubMed
  11. J Immunother. 2012 Jan;35(1):54-65 - PubMed
  12. Ann Surg Oncol. 2006 Aug;13(8):1085-98 - PubMed
  13. Clin Cancer Res. 2002 Aug;8(8):2553-62 - PubMed
  14. Immunology. 2008 Feb;123(2):157-63 - PubMed
  15. J Immunol. 2004 Jun 1;172(11):6598-606 - PubMed
  16. Int J Cancer. 1999 May 17;81(4):573-9 - PubMed
  17. J Immunol. 2003 Dec 1;171(11):5931-9 - PubMed
  18. Semin Oncol. 2015 Dec;42(6):887-95 - PubMed
  19. Cancer Lett. 2013 Aug 19;336(2):253-9 - PubMed
  20. Breast Cancer Res Treat. 2016 Feb;155(3):541-9 - PubMed
  21. Breast Cancer Res Treat. 2015 Jan;149(1):5-15 - PubMed
  22. Immune Netw. 2009 Dec;9(6):209-35 - PubMed
  23. Anticancer Res. 2013 May;33(5):2233-8 - PubMed
  24. Curr Breast Cancer Rep. 2014 Sep 1;6(3):169-182 - PubMed
  25. Oncoimmunology. 2015 Apr 1;4(10):e1022301 - PubMed
  26. Cancer Immunol Immunother. 2008 Oct;57(10):1511-21 - PubMed
  27. J Clin Oncol. 2009 Oct 1;27(28):4685-92 - PubMed
  28. Cancer Res. 2002 Jul 15;62(14):4132-41 - PubMed
  29. Clin Cancer Res. 2009 Dec 15;15(24):7479-7491 - PubMed
  30. Cancer. 2012 May 15;118(10):2594-602 - PubMed
  31. Curr Treat Options Oncol. 2014 Mar;15(1):41-54 - PubMed
  32. J Clin Oncol. 2008 Apr 10;26(11):1789-96 - PubMed
  33. Clin Exp Immunol. 2010 Jan;159(1):93-9 - PubMed
  34. Future Oncol. 2012 Oct;8(10):1273-99 - PubMed
  35. J Am Coll Surg. 2002 Apr;194(4):488-501 - PubMed
  36. Oncotarget. 2015 Sep 29;6(29):28173-82 - PubMed
  37. Front Oncol. 2014 Sep 29;4:266 - PubMed
  38. Cancer. 2012 Sep 1;118(17):4354-62 - PubMed
  39. Expert Rev Anticancer Ther. 2011 Feb;11(2):263-75 - PubMed
  40. PLoS One. 2013 Nov 11;8(11):e74698 - PubMed
  41. JAMA Oncol. 2016 Feb;2(2):242-6 - PubMed
  42. Crit Rev Immunol. 2000;20(1):17-56 - PubMed
  43. J Clin Oncol. 2015 Mar 1;33(7):701-8 - PubMed
  44. J Huazhong Univ Sci Technolog Med Sci. 2006;26(5):573-5 - PubMed
  45. Clin Lab. 2014;60(7):1145-51 - PubMed
  46. J Clin Oncol. 2002 Feb 1;20(3):719-26 - PubMed
  47. J Clin Oncol. 2011 Sep 1;29(25):3351-7 - PubMed
  48. Int Rev Immunol. 2001 Oct;20(5):535-46 - PubMed
  49. Clin Cancer Res. 2016 Aug 15;22(16):4133-44 - PubMed
  50. Lancet Oncol. 2012 Jan;13(1):25-32 - PubMed
  51. Front Immunol. 2015 Jun 02;6:271 - PubMed
  52. Front Immunol. 2014 Jun 04;5:261 - PubMed
  53. J Pathol. 2003 Jul;200(3):290-7 - PubMed
  54. Cancer Res. 2009 Dec 15;69(24):9330-6 - PubMed
  55. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1386-9 - PubMed
  56. Clin Cancer Res. 2009 Apr 15;15(8):2895-904 - PubMed
  57. Breast Cancer Res Treat. 2016 Apr;156(2):237-47 - PubMed
  58. JAMA Oncol. 2016 Jan;2(1):56-64 - PubMed
  59. Breast Cancer Res Treat. 2016 May;157(1):55-63 - PubMed
  60. Ann Oncol. 2001;12 Suppl 1:S15-9 - PubMed
  61. Semin Oncol. 2001 Oct;28(5 Suppl 16):27-32 - PubMed
  62. J Immunother. 2011 Jun;34(5):409-18 - PubMed
  63. J Immunol. 2012 Aug 1;189(3):1162-72 - PubMed
  64. Oncoimmunology. 2014 Jan 1;3(1):e27296 - PubMed
  65. N Engl J Med. 2006 Dec 28;355(26):2733-43 - PubMed
  66. Cancer Immunol Res. 2014 Feb;2(2):91-8 - PubMed
  67. J Clin Oncol. 2011 May 20;29(15):1949-55 - PubMed
  68. J Transl Med. 2012 Feb 10;10:28 - PubMed
  69. Lancet. 2010 Jan 30;375(9712):377-84 - PubMed
  70. Cancer Treat Rev. 2016 May;46:9-19 - PubMed
  71. Lancet. 2012 Feb 18;379(9816):633-40 - PubMed
  72. Int J Cancer. 1999 Aug 20;84(4):339-43 - PubMed
  73. JAMA Oncol. 2015 Jul;1(4):448-54 - PubMed
  74. Nat Rev Cancer. 2012 Mar 22;12(4):252-64 - PubMed
  75. Cancer Res. 1999 Oct 15;59(20):5356-64 - PubMed
  76. Ann Oncol. 2013 Aug;24(8):1999-2004 - PubMed
  77. Clin Cancer Res. 2002 May;8(5):1014-8 - PubMed
  78. N Engl J Med. 2012 Nov 8;367(19):1847-8 - PubMed
  79. Cancer Immunol Res. 2015 May;3(5):455-63 - PubMed
  80. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E319-27 - PubMed
  81. J Immunol. 2002 Sep 1;169(5):2756-61 - PubMed
  82. Breast Cancer Res. 2015 May 23;17:71 - PubMed
  83. Oncotarget. 2016 Jul 12;7(28):44288-44298 - PubMed
  84. Ann Surg Oncol. 2006 Sep;13(9):1252-8 - PubMed
  85. Cancer Med. 2016 Jul;5(7):1607-18 - PubMed
  86. J Surg Oncol. 2011 Oct;104(5):458-65 - PubMed
  87. Immunology. 2008 Mar;123(3):326-38 - PubMed
  88. Cancer Cell. 2010 Nov 16;18(5):485-98 - PubMed

Publication Types

Grant support